Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New embolization procedure could bring relief to arthritic fingers

NCT ID NCT06611007

Symptom relief Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if a procedure called arterial embolization using Lipiodol is safe for people with painful hand osteoarthritis that hasn't improved with standard treatments. Fifteen participants will receive the procedure and be followed for 6 months to track side effects, pain levels, and hand function. The goal is to see if blocking certain blood vessels can reduce pain and improve daily use of the hands.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥ 40 years. * Osteoarthritis of the hand according to American College of Rheumatology criteria 1990 * Osteoarthritis affecting at least two proximal and/or distal interphalangeal joints with a radiological Kellgren-Lawrence stage ≥ 2. * Symptomatic osteoarthritis within the last 3 months. * Visual analogue pain scale of the hand to be treated ≥ 40/100 mm (most painful hand). * Inadequate response, adverse effects and/or contraindication to NSAIDs and non-opioid analgesics. * Patient affiliated to french social security or a similar health assurance. Exclusion Criteria: * History of allergy to iodinated contrast media, LipiodolⓇ or poppies. * Vasomotor disorders (Raynaud\'s syndrome, scleroderma, acrocyanosis). * Stenosis (\>50%) or known atheromatous arterial occlusion of the upper limbs. * Obliterative arterial disease of the lower limbs at the critical ischaemia stage. * Severe to end-stage chronic renal insufficiency (glomerular filtration rate \< 30ml/min/1.73m2), dialysis or renal transplant. * Arteritis such as thromboangiitis obliterans disease or other diseases * Previous thrombosis/dissection of the radial artery. * Chronic inflammatory rheumatic disease (rheumatoid arthritis, psoriatic arthritis, microcrystalline arthritis, etc.). * Known hyperthyroidism or large multinodular goiter. * Traumatic lesions, haemorrhages or chronic bleeding in the hand (not completely resolved within 3 months of the start of the lesion) requiring embolisation. * Pregnant or breast-feeding. * Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code and/or who do not speak French. * Patients in a period of exclusion or in the course of another interventional clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hand osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis susceptibility 2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Grenoble Alpes - Sud site

    RECRUITING

    Échirolles, 38130, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.